Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation

Publisher： Bentham Science Publishers

E-ISSN： 1875-6301|2|3|223-229

ISSN： 1573-3947

Source： Current Cancer Therapy Reviews, Vol.2, Iss.3, 2006-08, pp. : 223-229

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cytoprotection and Immunomodulation in Cancer Therapy

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 4, Iss. 6, 2004-11 ,pp. : 479-490

Bentham Science Publishers

Access to resources Recommend Favorite

Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?

By Kirkali Ziya   Tüüzel Emre  

Future Oncology, Vol. 5, Iss. 6, 2009-08 ,pp. : 871-888

Future Medicine

Access to resources Recommend Favorite

Development and validation of the functional assessment of cancer therapy–antiangiogenesis subscale

By  

Cancer Medicine, Vol. 4, Iss. 5, 2015-05 ,pp. : 690-698

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antitumor activity of Pulsatilla koreana extract in anaplastic thyroid cancer via apoptosis and anti-angiogenesis

By              

Molecular Medicine Reports, Vol. 7, Iss. 1, 2013-01 ,pp. : 26-30

Spandidos Publications

Access to resources Recommend Favorite

Small Molecules for Immunomodulation in Cancer: A Review

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 15, Iss. 4, 2015-05 ,pp. : 433-452

Bentham Science Publishers

Access to resources Recommend Favorite